www.bioduro-sundia.com<\/a>。<\/p> \n关于DigmBio<\/b><\/p> \n
DigmBio, founded in April 2020<\/span>, is a pioneering biotech company headquartered in Korea, dedicated to developing innovative pharmaceuticals targeting critical unmet medical needs. Our management team has decades of collective experience in new drug development and global clinical trials, particularly in small-molecule therapeutics.<\/p> \nDigmBio's primary focus lies in identifying and advancing first-in-class therapeutics with the potential to address unmet medical needs, with a strategic emphasis on leveraging early licensing-out opportunities during the preclinical or phase 1 stages. Their pipeline encompasses therapies for oncology, Alzheimer's disease, and other CNS diseases including Parkinson's disease, along with a KRAS-targeted molecular glue.<\/p>"];
$("#dvExtra").html(content_array[0]);})();